Login to Your Account

Esbriet Wins EMEA Approval, InterMune Plans Fall Launch

By Jennifer Boggs

Friday, March 4, 2011
InterMune Inc.'s idiopathic pulmonary fibrosis (IPF) drug pirfenidone still faces some regulatory hurdles in the U.S., but the Brisbane, Calif.-based company is set to roll out its commercialization force in Europe this fall following official marketing authorization of pirfenidone, branded Esbriet, in mild to moderate IPF.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription